For lung cancer patients who experience grade 3/4 toxicity from a PD-1 inhibitor necessitating cessation of therapy, but whose tumor has responded to the treatment, do you consider restarting PD-1 inhibitor therapy at the time when they progress again?   

Would you consider giving the therapy with concominant steroids, or with a dose reduction?

Answer from: Medical Oncologist at Academic Institution